NFKB1 and diffuse large B-cell lymphoma: Previous studies proved that MI-2 inhibited ABC-DLBCL and melanoma tumor growth in vivo and inhibited MALT1 proteolytic activity and NF-κB activation in vitro (Fontan et al., 2012; Saba et al., 2017; Di Pilato et al., 2019).